First Aussie doses bring Imugene major step closer to 'quicker, cheaper' non-Hodgkin’s lymphoma care

Perhaps most crucially, it could also expand accessibility for patients with limited options.

(Testing started in early November, as reported by HotCopper at the time.)

This spearhead into Aussie testing comes after Imugene collected “promising data” through its U.S.-based trials; three patients in State-side testing had zero signs of the cancer despite relapsing after other, similar treatments.

“[This is] a significant milestone for Imugene and for Australian patients battling this devastating disease,” Imugene’s CEO Leslie Chong declared today.

“The trial’s opening… reflects our commitment to accelerating innovative, off-the-shelf immunotherapies that have the potential to improve outcomes for Australian patients with relapsed or refractory Diffuse large B-cell lymphoma.

Diffuse large B-cell lymphoma (DLBCL) is among the most common non-Hodgkin’s lymphoma subtypes. It impacts more than 80,000 people each calendar year.

The company will next expand its Aussie recruitment “across multiple sites.”